Clinical trials: Prostate Cancer, Castration Resistant
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Metastatic Castration-Resistant Prostate Cancer
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
- Trial name
- NCT02711956
- Testing
- ZEN003694, Enzalutamide
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Zenith Epigenetics
Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma
A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will receive SHR3680.
- Trial name
- NCT02691975
- Testing
- SHR3680
- Where
- 12 sites in China
- Volunteers
- 197 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
[177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer.
The study aims to evaluate the stability and efficacy after administration of [177Lu]Ludotadipep in patients with metastatic castration resistant prostate cancer (mCRPC), with dose-escalation applied to determine the appropriate…
- Trial name
- NCT04509557
- Testing
- [177Lu]Ludotadipep
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- FutureChem
Castration-Resistant Prostatic Cancer, Metastasis
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06863272
- Testing
- Docetaxel, Ifinatamab Deruxtecan, Opevesostat
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 360 people
- Sponsor
- Merck Sharp & Dohme LLC
Castration-resistant Prostate Cancer
ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
This is a safety, feasibility and pharmacokinetic study to confirm that the recommended safe dose and schedule of ModraDoc006/r (oral docetaxel with ritonavir) as determined in a previous phase I study is also safe and feasible…
- Trial name
- NCT03136640
- Testing
- ModraDoc006/r
- Where
- 4 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Modra Pharmaceuticals
Prostate Cancer, Prostate Cancer Metastatic
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05361915
- Testing
- Abivertinib, Abiraterone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Sorrento Therapeutics, Inc.
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of…
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
- Trial name
- BActinium-1 (NCT07581184)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Aktis Oncology, Inc.
Prostate Cancer
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic…
- Trial name
- NCT01193244
- Testing
- Orteronel, Prednisone
- Where
- 240 sites in United States, Australia and 38 more
- Volunteers
- 1,560 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer Metastatic
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
The aim of this trial is to evaluate SHR3680 combined with Docetaxel to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's Time to prostate specific antigen (PSA) progression is superior to…
- Trial name
- NCT04603833
- Testing
- SHR3680+Docetaxel, SHR3680, Docetaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-resistant Prostate Cancer
Post Marketing Study on Pluvicto in Korea
Post marketing study on Pluvicto in Korea
- Trial name
- NCT06514521
- Testing
- Lutetium vipivotide tetraxetan
- Where
- 12 sites in South Korea
- Volunteers
- 278 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer
The purpose of this study is to assess pharmacodynamics and safety of JNJ-212082 in order to select the recommended dose of JNJ-212082 for patients with castration resistant prostate cancer.
- Trial name
- NCT01186484
- Testing
- JNJ-212082
- Where
- 5 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Janssen Pharmaceutical K.K.
Metastatic Castration-resistant Prostate Cancer, MCRPC
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone…
- Trial name
- NCT06890832
- Testing
- 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel
- Volunteers
- 75 people
- Sponsor
- Jina Pharmaceuticals Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle.
- Conditions
- Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
- Trial name
- NCT04729114
- Testing
- PRL-02 injection, prednisone, dexamethasone
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Bone Metastases, Castration-Resistant Prostate Cancer
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and…
- Trial name
- NCT01106352
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Where
- 7 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the…
- Trial name
- NCT05818683
- Testing
- Pasritamig, Cetrelimab, Cabazitaxel
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 300 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration-Resistant Prostate Cancer Patients
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment.
- Trial name
- NCT07514065
- Testing
- Treatment arm: TSL2109 capsules。Oral administration。
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Advanced Solid Tumor, HER2-negative Breast Cancer
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
- Trial name
- NCT06334432
- Testing
- NUV-1511
- Where
- 8 sites in United States
- Volunteers
- 466 people
- Sponsor
- Nuvation Bio Inc.